FEATURES OF DYSLIPOPROTEINEMIA IN TYPE 2 DIABETES MELLITUS PATIENTS WITH PRIOR MYOCARDIAL INFARCTION
Article PDF

Keywords

type 2 diabetes mellitus, postinfarction cardiosclerosis, dyslipoproteinemia

Abstract views: 42
PDF Downloads: 31

How to Cite

Altunina , N. (2020). FEATURES OF DYSLIPOPROTEINEMIA IN TYPE 2 DIABETES MELLITUS PATIENTS WITH PRIOR MYOCARDIAL INFARCTION. Medical Science of Ukraine (MSU), 16(3), 27-32. https://doi.org/10.32345/2664-4738.3.2020.5

Abstract

Relevance. In diabetes mellitus (DM), atherosclerotic plaques contain more fat, are more inflammatory, and show a higher risk of thrombus formation than in individuals without diabetes. One of the significant factors in the development and progression of atherosclerosis in these patients is atherogenic dyslipidemia, which includes a wide range of disorders and often precedes the onset of diabetes for several years. Therefore, it is relevant to study the features of dyslipidemia in patients with diabetes after myocardial infarction (MI).

Objective: to study changes in blood lipid spectrum parameters, including Apolipoproteins (Apo A-1, Apo B) and lipoprotein (a), in postinfarction patients with type 2 DM.

Materials and methods. 119 patients (77 men and 42 women; mean age 61.09 ± 0.92 years) were examined, of which 42 were patients with coronary heart disease (CHD) who suffered from MI and type 2 diabetes (main group), 39 patients with a history of MI without concomitant diabetes (comparison group I) and 38 patients with type 2 diabetes without MI (comparison group II). The control group consisted of 30 healthy individuals, comparable in age and sex. Total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDLC) were determined in venous serum by enzymatic colorimetric method. According to the formulas, the level of cholesterol in very-low-density lipoproteins (VLDLC) was calculated; cholesterol in low-density lipoprotein (LDLC), coefficient of atherogenicity (CA). The level of lipoprotein (a) – LP (a), Apo A-1, and Apo B were determined by immunoturbidimetry. Blood sampling in patients was performed on an empty stomach.

Results. In the main group, significantly higher rates of TC, TG, LDLC, VLDLC, AF, Apo B, and the ratio of Apo B/Apo A-1, compared with non-diabetic postinfarction patients. At the same time, there was a significantly lower concentration of HDLC, Apo A-1, and LP (a) – in patients with a history of diabetes mellitus. When comparing the indicators of patients in the main group with patients with isolated type 2 diabetes, there were significantly higher levels of LDL cholesterol and CA, as well as significantly lower concentrations of HDL cholesterol and apo A-1 in patients of the main group. The analysis of lipid metabolism in the comparison groups revealed a difference in the level of TG, LDL cholesterol, and Apo B, which have higher levels in patients with isolated type 2 diabetes, and the level of LP (a) – significantly higher in postinfarction patients, in contrast to diabetics. The results indicate deeper disorders of lipid metabolism in post-infarction patients with diabetes than in non-diabetic post-infarction patients, which may be due to insulin resistance, hyperinsulinemia, and hyperglycemia.

Conclusions. Dyslipoproteinemia in postinfarction patients with type 2 diabetes is characterized by a decrease in the content of antiatherogenic HDL cholesterol and its protein Apo A-1, moderate hypertriglyceridemia, increased levels of LDL cholesterol, VLDL cholesterol, and Apo B, which causes higher values of cholesterol and increases AF. Elevations in lipid profile parameters such as TG, LDL cholesterol, and Apo B are more associated with diabetes, while higher concentrations of LP (a) are characteristic of postinfarction non-diabetic patients.

https://doi.org/10.32345/2664-4738.3.2020.5
Article PDF

References

1. Aleksandrov A.A., Bondarenko I.Z., Kukharenko S.S., Yadrikhinskaya M.N., Martyanova I.I., Solyanik Yu.A., Drozdova E.N., Mayorov A.Yu. [Diabetes mellitus and coronary heart disease: search for a solution]. Diabetes mellitus. 2005; 3: 34-8. [in Russian]. URL: https://cyberleninka.ru/article/n/saharnyy-diabet-i-ishemicheskaya-bolezn-serdtsa-poiski-resheniya
2. Alexandrov A.A. [Myocardial infarction and diabetes mellitus: "Munich Agreement"]. Diseases of the heart and blood vessels. 2007; 2(2): 4-11. [in Russian]. URL: http://old.consilium-medicum.com/media/bss/07_02/4.shtml
3. Alexandrov A.A. [Cardiovascular complications and modern algorithm of antihyperglycemic therapy: "Florentine perspective"]. Russian medical journal. 2010; 14: 879-84. [in Russian]. URL: https://www.rmj.ru/articles/endokrinologiya/Serdechnososudistye_osloghneniya_i_sovremennyy__algoritm_saharosnighayuschey_terapii__Florentiyskaya_perspektiva/
4. Vel'kov V.V. [How to prevent heart attacks and strokes: predictors]. Polyclinic. Laboratory diagnostics. 2008; 3: 56-9. [in Russian]. URL: http://www.poliklin.ru/articels/08_03/16_(58-61).pdf
5. Dedov I.I., Melnichenko G.A. [Endocrinology: national guidelines]. Moscow: GEOTAR-Media, 2008. 1072 p. [in Russian]. URL: https://www.rosmedlib.ru/book/ISBN9785970450833.html
6. Dedov I.I., Shestakova M.V., Mayorov A.Yu. [Algorithms for specialized medical care for patients with diabetes mellitus]. Moscow: Media Sphere, 2007. 112 p. [in Russian]. URL: http://webmed.irkutsk.ru/doc/pdf/algosd.pdf
7. Klimov A.N., Nikulcheva N.G. [Lipids, lipoproteins and atherosclerosis]. St. Petersburg: Peter. Press, 1995. 304 p. [in Russian]. URL: https://www.libex.ru/detail/book703548.html
8. Mitchenko O.I., Lutai M.I. Dyslipidemias: diagnosis, prevention and treatment. Methodical recommendations of the Association of Cardiologists of Ukraine. Kyiv, 2011. 48 p. [in Ukrainian]. URL: http://strazhesko.org.ua/upload/2014/02/20/guidelines_dyslipid_2011_new.pdf
9. Brunzell J.D., Hokanson J.E. Dyslipidemia of central obesity and insulin resistance. Diabetes Care. 1999; 22 (Suppl. 3): C10-C13. PMID: 10189557.
10. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003; 361: 2005-16. DOI: https://doi.org/10.1016/s0140-6736(03)13636-7.
11. Erqou S., Thompson A., Di Angelantonio E. [et al.] Apolipoprotein (a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J. Am. Coll. Cardiol. 2010; 55: 2160-7. DOI: https://doi.org/10.1016/j.jacc.2009.10.080
12. Friedewald W.T., Levy R.I., Fredricson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972; 18(6): 499-502. PMID: 4337382
13. Ginsberg H.N., Huang L.S. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J. Cardiovasc. Risk. 2000 Oct; 7(5): 325-31. DOI: https://doi.org/10.1177/204748730000700505
14. Hurst R.T., Lee R.W. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann. Intern. Med. 2003 Nov 18; 139(10): 824-34. DOI: https://doi.org/10.7326/0003-4819-139-10-200311180-00010
15. Malmberg K., Ryden L., Wedel H., Birkeland K., Bootsma A., Dickstein K., Efendic S., Fisher M., Hamsten A., Herlitz J., Hildebrandt P., MacLeod K., Laakso M., Torp-Pedersen C., Waldenström A., DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur. Heart J. 2005 Apr; 26(7): 650-61. DOI: https://doi.org/10.1093/eurheartj/ehi199
16. Nordestgaard BG, Chapman MJ, Ray K., Borén J., Andreotti F., Watts G.F., Ginsberg H., Amarenco P., Catapano A., Descamps O.S., Fisher E., Kovanen P.T., Kuivenhoven J.A., Lesnik Ph., Masana L., Reiner Z., Taskinen M.-R., Tokgözoglu L., Tybjærg-Hansen A., European Atherosclerosis Society Consensus Panel. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur. Heart J. 2010 Dec; 31(23): 2844-53. DOI: https://doi.org/10.1093/eurheartj/ehq386
17. Ryden L., Grant P.J., Anker S.D. [et al.] ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart J. 2013 Oct; 34(39): 3035-87. DOI: https://doi.org/10.1093/eurheartj/eht108
18. Sorrentino SA, Besler C, Rohrer L., Meyer M., Heinrich K., Bahlmann F.H., Mueller M., Horváth T., Doerries C., Heinemann M., Flemmer S., Markowski A., Manes C., Bahr M.J., Haller H., Eckardstein A., Drexler H., Landmesser U. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010 Jan 5; 121(1): 110-22. DOI: https://doi.org/10.1161/circulationaha.108.836346
19. United Kingdom Prospective Diabetes Study: Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex (UKPDS 27). Diabetes Care. 1997 Nov; 20(11): 1683-7. DOI: https://doi.org/10.2337/diacare.20.11.1683
20. Vijayaraghavan K. Treatment of dyslipidemia in patients with type 2 diabetes. Lipids in Health and Disease. 2010; 9: 144-156. DOI: https://dx.doi.org/10.1186%2F1476-511X-9-144
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.